Skip to main content
Inotiv, Inc. logo

Inotiv, Inc. — Investor Relations & Filings

Ticker · NOTV ISIN · US09058M1036 LEI · 549300FH5Z13X0Q5SK81 US Professional, scientific and technical activities
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2026-06-03 Capital/Financing Update
Country US United States of America
Listing US NOTV

About Inotiv, Inc.

https://www.inotiv.com/

Inotiv, Inc. is a contract research organization (CRO) providing a comprehensive range of nonclinical and analytical drug discovery and development services. Key service areas include general toxicology, pathology, histology, drug metabolism and pharmacokinetics (DMPK), and bioanalytical solutions. The company also offers specialized services such as digital pathology with AI-driven image analysis, monoclonal antibody production, and developmental and reproductive toxicology (DART) studies. In addition to its CRO services, Inotiv is a major provider of research models and related products. This includes a wide array of animal models, genetically engineered model services (GEMS), contract breeding, surgical services, and Teklad laboratory animal diets and bedding. Inotiv serves clients across the pharmaceutical, biotechnology, medical device, academic, and government sectors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 88% confidence The document is a Form 8-K “Current Report” detailing a prepackaged debt restructuring support agreement, including debtor-in-possession (DIP) financing and exit financing facilities and the conversion of funded debt into equity. This constitutes a material capital structure change and financing activity update rather than an earnings release, merger proxy, or management discussion. Therefore, it aligns with the “Capital/Financing Update” category.
2026-06-03 English
8-K
Capital/Financing Update Classification · 91% confidence The document is a Form 8-K “Current Report” disclosing the entry into a Supplemental Indenture for its Convertible Senior Notes (extending the interest payment grace period). This constitutes an update on the company’s financing activities and a change to its capital structure. It is neither a full annual or quarterly report nor mere publication notice. It matches the definition of a Capital/Financing Update.
2026-06-01 English
FORM 8-K
Capital/Financing Update Classification · 90% confidence The document is an SEC Form 8-K “Current Report” primarily disclosing entry into a material definitive agreement – specifically the Ninth Amendment to the Credit Agreement establishing a new $40 million bridge facility (term loan), covenant modifications, and a supplemental indenture amending the convertible notes indenture. These are detailed financing/capital structure changes, including borrowing, guarantees, fees, and covenant waivers. Thus, it fits the “Capital/Financing Update” category (CAP). Although it also includes director appointments, the core focus is the financing amendment.
2026-05-18 English
10-Q
Interim / Quarterly Report Q2 2026
2026-05-11 English
8-K
Capital/Financing Update Classification · 82% confidence The document is a Form 8-K filed under the Securities Exchange Act of 1934, reporting an "Other Event" on May 4, 2026, concerning a waiver under the company’s existing Credit Agreement (an amendment/waiver of a financing covenant). This is a specific financing-related update rather than a full financial report or earnings release. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-05 English
8-K
Regulatory Filings
2026-04-21 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.